QED-203 / UniQuest - LARVOL DELTA

QED-203, a dual TRPV6 and AR small molecule preclinical candidate for advanced prostate cancer resistant to standard of care (AACR 2026) - "QED-203 maintains effectiveness in prostate cancer cell lines that are resistant to next generation AR inhibitors including enzalutamide with multiple resistance mechanisms. QED-203 thus targets a novel dual axis pathway (AR/TRPV6) to supress prostate cancer growth. QED-203 may offer a new opportunity to treat prostate cancer patients who have developed resistance to next generation AR therapies, where there is a clear clinical need for new therapeutic approaches"

Metastases • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • TRPV6